PetVivo Holdings, Inc. (PETV) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong revenue growth and market expansion potential, particularly in the animal health sector. Despite a decrease in gross margins and an increased net loss, the company's strategic initiatives, including partnerships and product launches, are promising. The Q&A highlighted management's transparency about revenue sources and adoption challenges, though specifics were lacking. The strategic partnerships and record revenue growth are positive indicators. Given these factors, the stock price is likely to see a positive movement over the next two weeks.
Key Financial Performance
Total Revenue for Q2 FY2026 $303,000, a 51% increase year-over-year. This growth was driven by the expanded North American distributor network, which increased sales by 35%, and the introduction of new product offerings like PrecisePRP.
Revenue for the First Half of FY2026 More than $600,000, an 85% increase year-over-year. This reflects the success of sales and marketing efforts and the expansion of the distributor network and in-house sales force.
Gross Profit for Q2 FY2026 $220,000 or 72.6% of revenues, a 23% increase from $180,000 in the same quarter a year ago. The gross margin decreased from 89.5% to 72.6% due to the sales mix including the new PrecisePRP product, which carries a smaller margin.
Total Operating Expenses for Q2 FY2026 $2.3 million, a 3% decrease from $2.4 million a year ago. This reduction was due to decreased research and development costs and a strategic cost reduction and restructuring program.
Operating Loss for Q2 FY2026 Approximately $2 million, a 5% decrease year-over-year. This was due to increased sales and lower operating expenses.
Net Loss for Q2 FY2026 $3 million or $0.11 per share, compared to $2.2 million or $0.11 per share a year ago. The increased loss was due to higher interest expenses from debt discount, though excluding this, the net loss improved by 5% to $2.1 million.
Net Cash Used in Operating Activities for Q2 FY2026 $3.8 million, an increase from $3.1 million a year ago. This was primarily due to increased inventory purchases for the new PrecisePRP product line and settlement payments to trade vendors.
Available Cash as of September 30, 2025 $768,000, up from $220,000 as of March 31, 2025. The increase was due to financing activities conducted during the quarter.
Total Liabilities as of September 30, 2025 $1.1 million, a 79% decrease from $5.1 million as of March 31, 2025. This was due to the extinguishment of derivative liabilities and the conversion of all convertible notes to common stock.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Spryng with OsteoCushion technology: Continued growth in product momentum, used by over 1,200 veterinary clinics across all 50 states, and expanded to international markets including Mexico and Europe.
PrecisePRP: Breakthrough regenerative health product for dogs and horses, generating increased revenue and adoption in the canine market, with reintroduction to the equine market.
Agentic Pet AI technology: Exclusive 10-year licensing agreement for AI technology to enhance veterinary diagnostics and reduce client acquisition costs.
PiezoBioMembrane collaboration: Advancing research on biodegradable piezoelectric materials for regenerative applications in animals and humans.
U.S. market: Distributor network sales increased by 35%, reaching $237,000, representing 75% of total revenues. Total revenue for the quarter increased by 51% to $303,000.
International market: Entered European market with U.K.-based Nupsala Group and expanded in Mexico, targeting high-growth markets with significant CAGR projections.
Sales and marketing efforts: Expanded in-house sales force, added experienced territory managers, and implemented new CRM system (HubSpot) to enhance sales tracking and follow-ups.
Cost management: Operating expenses decreased by 3% due to strategic cost reduction and restructuring programs.
Partnerships and collaborations: Formed partnerships with VetStem, Commonwealth Markets, and Digital Landia to enhance product offerings and market reach.
Board appointment: Appointed Josh Ruben to the Board of Directors, bringing expertise in healthcare, finance, and corporate strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Expansion Risks: The company is expanding into international markets such as Europe and Mexico, which introduces risks related to regulatory compliance, cultural differences, and market acceptance. Additionally, the European market is highly competitive, and the company may face challenges in establishing a foothold.
Financial Sustainability: Despite revenue growth, the company reported a net loss of $3 million for the quarter, driven by increased interest expenses and operating costs. This raises concerns about the company's ability to achieve profitability in the near term.
Product Margin Pressure: The introduction of the new PrecisePRP product has led to a decrease in gross margins, as it carries a smaller margin compared to other products. This could impact overall profitability if the product mix continues to shift.
Supply Chain and Inventory Management: The company has increased inventory purchases to meet growing demand, which has led to higher cash usage in operating activities. This could pose risks if demand does not materialize as expected or if inventory management issues arise.
Strategic Execution Risks: The company is pursuing multiple strategic initiatives, including new product launches, partnerships, and technological integrations. Managing these simultaneously could strain resources and lead to execution challenges.
Regulatory and Compliance Risks: The company’s entry into new markets and the development of new technologies like AI and regenerative medicine may face regulatory hurdles, which could delay product launches or increase costs.
Economic and Market Conditions: The company is operating in a high-growth but competitive market. Economic downturns or changes in market conditions could adversely affect demand for its products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued strong sales momentum and market penetration for the duration of fiscal 2026 and beyond, with projections for another year of record growth and improving bottom line. The third and fourth quarters are anticipated to be the strongest due to increased industry events and product awareness.
Market Expansion: The U.S. animal health market is expected to double to $11.3 billion by 2030, providing significant growth opportunities. The company is also expanding into high-growth international markets, including Mexico and Europe, with the European animal market projected to grow at a CAGR of 8.6% to $34.8 billion by 2033.
Product Development: The company is advancing the development of new products, including a functional Spryng-like product in collaboration with PiezoBioMembrane. This product is expected to enter Stage C testing for safety and efficacy in the second calendar quarter of next year.
Technological Integration: The company plans to integrate Digital Landia's agentic AI technology into its platform, with a commercial launch anticipated in the near future. This technology aims to reduce client acquisition costs and enhance access to the Gen Z pet parent demographic.
Product Launches: The company is preparing for a larger launch of its PrecisePRP equine product at the AAP event in December in Denver.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many clinics are heavy users of the product?
A:The CEO, John Lai, mentioned that the adoption process for the product takes 6 months to a year, and while they are growing the number of clinics using the product, he did not provide specific numbers on heavy users.
Q:Can you break down the revenue between Spryng and PRP?
A:The CFO, Garry Lowenthal, stated that 42% of the revenue in the last quarter came from PRP and 58% from Spryng. This breakdown was specific to canine products and did not include equine products.
Q:Is the PRP revenue just from the canine version?
A:Yes, the PRP revenue mentioned was solely from the canine version. The equine PRP started shipping only a month ago.
Q:Do any corporate clinics adopt your product corporate-wide?
A:No, corporate-wide adoption has not occurred. Some veterinarians within corporate groups use the product, but corporate mandates for its use have not been established.
Q:Are there products that have corporate blessings for use?
A:Yes, common drugs like NSAIDs, anti-inflammatories, and flea and tick medications often have corporate approval. However, specialized products like Spryng require a learning curve and individual vet approval.
Q:Can you break down revenue between companion animals and equine?
A:The CFO, Garry Lowenthal, mentioned that they plan to provide segment reporting in the future, breaking down revenue between companion animals and equine. Currently, equine PRP is in its early stages of launch.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers on heavy users of the product, citing the time-consuming adoption process. Additionally, while they acknowledged tracking revenue between companion animals and equine, they did not provide a current breakdown, stating it would be available in future reporting.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI technology
BB
Commonwealth
Digital Landia
Group
Mexico
OTCQX
PrecisePRP product
Sales
Stage
United
VGP
VetStem
adviser
canine
client
collaboration
future
health care
human
launch
marketing effort
marketplace
material
momentum
note
order
parent
partner
patient
pet AI
platform
practice
product offering
progress
rate
record
revenue increase
sale marketing
stage
treatment
vendor
PETV Transcript
PetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call Transcript
Unknown2-17
The earnings call summary indicates mixed signals: improved balance sheet and strategic cost reductions are positive, but increased operating loss and lack of clear guidance are concerning. The Q&A reveals management's uncertainty about guidance and revenue expectations, which could worry investors. While there are promising developments in product launches and market expansion, the absence of NASDAQ listing plans and unclear future projections temper enthusiasm, leading to a neutral sentiment.
PetVivo Holdings, Inc. (PETV) Q2 2026 Earnings Call Transcript
Positive11-14
The earnings call revealed strong revenue growth and market expansion potential, particularly in the animal health sector. Despite a decrease in gross margins and an increased net loss, the company's strategic initiatives, including partnerships and product launches, are promising. The Q&A highlighted management's transparency about revenue sources and adoption challenges, though specifics were lacking. The strategic partnerships and record revenue growth are positive indicators. Given these factors, the stock price is likely to see a positive movement over the next two weeks.
PetVivo Holdings, Inc. (PETV) Q1 2026 Earnings Call Transcript
Unknown8-14
The earnings call summary shows mixed signals: strong revenue growth and new partnerships are positive, but high operating losses, cash flow concerns, and reliance on distributors are negative. The Q&A didn't reveal new insights or strong analyst sentiment. Despite record revenue growth, margin pressure and financial health concerns weigh heavily, balancing out the positives. Without clear guidance or market cap data, the overall sentiment is neutral, suggesting a stock price movement within the -2% to 2% range.
PetVivo Holdings, Inc. (PETV) Q4 2025 Earnings Call Transcript
Unknown6-30
The earnings call highlights financial challenges, including a net loss and cash constraints, despite revenue growth. Regulatory compliance issues and potential dilution from Series B conversion add to investor concerns. The Q&A reveals management's evasive responses and competitive pressures. While there is optimism about human trials, the overall sentiment is negative due to financial sustainability issues and market penetration challenges.
PETV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
